相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy
Dongho Kim et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Dasatinib 100 mg Once Daily Minimizes the Occurrence of Pleural Effusion in Patients With Chronic Myeloid Leukemia in Chronic Phase and Efficacy Is Unaffected in Patients who Develop Pleural Effusion
Kimmo Porkka et al.
CANCER (2010)
Renal failure associated with tyrosine kinase inhibitors-Case report and review of the literature
Anat Gafter-Gvili et al.
LEUKEMIA RESEARCH (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Acute Renal Failure under Dasatinib Therapy
Sultan Ozkurt et al.
RENAL FAILURE (2010)
Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?
Mark Goldblatt et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2009)
New dosing schedules of dasatinib for CML and adverse event management
Siu-Fun Wong
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
David Masiello et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2009)
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia
Sarah A. Holstein et al.
LEUKEMIA RESEARCH (2009)
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors
Kevin Kelly et al.
TARGETED ONCOLOGY (2009)
Partial Fanconi syndrome induced by imatinib therapy: A novel cause of urinary phosphate loss
Helene Francois et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2008)
Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis
Hugues de lavallade et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Metabolism and disposition of dasatinib after oral administration to humans
Lisa J. Christopher et al.
DRUG METABOLISM AND DISPOSITION (2008)
Role of platelet-derived growth factors in physiology and medicine
Johanna Andrae et al.
GENES & DEVELOPMENT (2008)
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
Neil P. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure
M. Sonmez et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2008)
Lung abnormalities after dasatinib treatment for chronic myeloid leukemia -: A case series
Anne Bergeron et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I trial of intermittent administration of sorafenib (BAY 43-9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)
A. Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial
Hagop Kantarjian et al.
BLOOD (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus et al.
BLOOD (2007)
Tumour lysis syndrome with acute renal failure during imatinib therapy
Ridvan Ali et al.
LEUKEMIA RESEARCH (2007)
Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease
C. Zoja et al.
KIDNEY INTERNATIONAL (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
John S. Tokarski et al.
CANCER RESEARCH (2006)
Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice
A Sadanaga et al.
ARTHRITIS AND RHEUMATISM (2005)
Acute renal failure secondary to imatinib mesylate treatment in prostate cancer
JR Foringer et al.
ANNALS OF PHARMACOTHERAPY (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume
GC Jayson et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Imatinib mesylate blocks a non-smad TGF-beta pathway and reduces renal fibrogenesis in vivo
SN Wang et al.
FASEB JOURNAL (2005)
Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice
M Lassila et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2005)
Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia
M Pou et al.
LEUKEMIA & LYMPHOMA (2003)
Hypersensitivity pneumonitis related to imatinib mesylate
A Bergeron et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571
C Kitiyakara et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2002)
Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase
A Vora et al.
ANNALS OF ONCOLOGY (2002)
分享论文
